Clinical Diagnosis

ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.

Striving to improve outcomes is important because of the negative effect of astigmatism on patients’ vision postoperatively.

Marking Glaucoma Awareness Month this month, Bausch + Lomb and the Glaucoma Research Foundation have released key findings from a survey of glaucoma patients that was designed to gain a greater understanding of the impact that hyperemia can have in the treatment and lives of people living with glaucoma.

The acquisition brings the Hydrus Microstent into Alcon’s global surgical portfolio. The company will leverage its global footprint and leadership in ophthalmology to drive future growth, bringing the device to more patients worldwide.

The rate of adverse events was low in this higher risk, difficult-to-manage population of special-needs children, noted Margaret Reynolds, MD.

The new procedure eliminates the need for scleral flaps by positioning the T-shaped IOL haptics in the scleral wall.

Clear communication, on-call services, and listening to your patients may keep them from expensive and often unnecessary emergency room visits.

Consecutive intravitreal dexamethasone treatments may be beneficial for patients with DME patients who had undergone a previous vitrectomy.

Delayed presentations and acute shortage of donor corneal tissues for emergency keratoplasty are among reasons given for adverse outcome.

The improvement became evident during an average time of 6 months.

The approach seems to provide high levels of spectacle independence and patients' satisfaction, with limited complications associated.

Approach shows potential as a promising second-line screening tool for patients with diabetes.

With every 10-year increase in patient age, the risk of the patients needing concomitant administration of steroid eye drops decreased by half, according to investigators.

A virtual, risk-based approach to preoperative medical evaluations for cataract surgery may be associated with safe and efficient outcomes, according to study investigators.

Analysis finds acceptable outcomes can be expected when pterygium surgery is performed by a supervised ophthalmology resident.

Spectacle independence is not the main factor that determines patients’ lens selections, according to study investigators.

According to the organization, the goal is to highlight and address the diverse and critical vision and eye health needs of children and to improve outcomes through advocacy, public health, education, and awareness.

The difference in visual acuities based on CST fluctuations in these patients with diabetic macular edema remained significant.

An elevated risk may be associated with the cataract type, case complexity, and history of diabetic macular edema or proliferative diabetic retinopathy.

SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.

According to the company, OK-101 displays both anti-inflammatory and ocular pain-reducing potential.

For surgeons, the decision goes beyond clarifying a patient’s vision.

Although graft rejection has not been associated with vaccinations, concern remains.

According to Lisa Nijm, MD, JD, patients can benefit from short-term, on-label treatment with a novel loteprednol formulation

Investigators say renal function could be used as a possible predictor for poor treatment response in certain patients with diabetic macular edema.

I-MED Pharma Inc., a Canadian-based firm, announced this week the expansion of its strategic partnership with ESW Vision in France to be their exclusive distributor in the United States.

TearLab Corp. announced that Adam Szaronos has been appointed president and CEO by the company's Board of Directors, effective immediately.

Investigators are hopeful that future research can focus on public health concerns of dry eye disease.

Researchers have now found that subjects who underwent cataract surgery had nearly 30% lower risk of developing dementia from any cause compared with those who did not.

Study shows statistically significant improvement for primary endpoint of bulbar conjunctival hyperemia for OTX-DED 0.2 mg and 0.3 mg formulations compared with vehicle hydrogel insert.